Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

Phase 4

Completed

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Bortezomib
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2018-01-31

Last Posted Date: 2022-09-27

Lead Sponsor: Takeda

Target Recruit Count: 45

Registration Number: NCT03416374

Locations: 🇯🇵
Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵
Kyorin University Hospital, Mitaka, Tokyo, Japan
🇯🇵
Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan

and more 20 locations

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Bortezomib
Drug: Lenalidomide
Drug: Melphalan
Drug: Carfilzomib
Drug: Dexamethasone
Drug: Prednisone

First Posted Date: 2018-01-26

Last Posted Date: 2024-05-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 265

Registration Number: NCT03412565

Locations: 🇺🇸
Cancer Center of Central Connecticut - Southington, Southington, Connecticut, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Avera Medical Group - Oncology & Hematology, Sioux Falls, South Dakota, United States

and more 60 locations

Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2018-01-25

Last Posted Date: 2023-03-29

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 18

Registration Number: NCT03411031

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

Phase 3

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: netupitant/palonosetron
Drug: fosnetupitant/ palonosetron
Drug: dexamethasone

First Posted Date: 2018-01-19

Last Posted Date: 2020-06-01

Lead Sponsor: Helsinn Healthcare SA

Target Recruit Count: 404

Registration Number: NCT03403712

Locations: 🇺🇸
CBCC Global Research, INC at Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸
Mercy Medical Center, Medical Oncology and Hematology, Baltimore, Maryland, United States

and more 37 locations

Preoperative High Dose Steroids for Liver Resection- Effect on Complications in the Immediate Postoperative Period

Phase 4

Completed

Conditions: Complication, Postoperative

Interventions: Drug: Dexamethasone
Drug: Methylprednisolone

First Posted Date: 2018-01-18

Last Posted Date: 2021-01-05

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 174

Registration Number: NCT03403517

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark

BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients

Not Applicable

Completed

Conditions: Amyloidosis; Systemic

Interventions: Drug: Doxycycline
Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2018-01-17

Last Posted Date: 2021-02-23

Lead Sponsor: Jian Li

Target Recruit Count: 140

Registration Number: NCT03401372

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

Phase 1

Completed

Conditions: Recurrent Plasma Cell Myeloma
T(11;14)

Interventions: Drug: Dexamethasone
Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis
Drug: Venetoclax

First Posted Date: 2018-01-16

Last Posted Date: 2024-11-04

Lead Sponsor: Mayo Clinic

Target Recruit Count: 8

Registration Number: NCT03399539

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States